{"result": "(\"entity\"<|>TIMIDIN FOSFORILASA<|>PERSON<|>Timidin fosforilasa is an enzyme whose deficiency is characterized by elevated levels of timidina and deoxiuridina in plasma, leading to various health issues.)\n##\n(\"entity\"<|>LEUCOENCEFALOPATÍA<|>EVENT<|>Leucoencefalopatía is a condition characterized by diffuse alterations in white matter, often associated with neurological symptoms.)\n##\n(\"entity\"<|>COENZIMA Q 10<|>PERSON<|>Coenzima Q 10 is an antioxidant and a crucial component of the mitochondrial respiratory chain, evaluated for its effects in mitochondrial diseases.)\n##\n(\"entity\"<|>CREATINA<|>PERSON<|>Creatina is a substance studied for its potential benefits in improving muscle strength in patients with mitochondrial diseases.)\n##\n(\"entity\"<|>ÁCIDO LÁCTICO<|>PERSON<|>Ácido láctico is a substance that may be elevated in patients with certain mitochondrial diseases, indicating metabolic issues.)\n##\n(\"entity\"<|>VITAMINA E<|>PERSON<|>Vitamina E is an antioxidant that has been evaluated for its clinical benefits in mitochondrial diseases but lacks evidence of efficacy.)\n##\n(\"entity\"<|>DHIROLOPATO<|>PERSON<|>Dihidrolipoato is an antioxidant studied in the context of mitochondrial diseases, with no clinical benefit demonstrated.)\n##\n(\"relationship\"<|>TIMIDIN FOSFORILASA<|>LEUCOENCEFALOPATÍA<|>Timidin fosforilasa deficiency is associated with leucoencefalopatía, as both are related to mitochondrial dysfunction<|>7)\n##\n(\"relationship\"<|>COENZIMA Q 10<|>LEUCOENCEFALOPATÍA<|>Coenzima Q 10 is recommended for treatment in mitochondrial diseases, which include leucoencefalopatía<|>5)\n##\n(\"relationship\"<|>CREATINA<|>LEUCOENCEFALOPATÍA<|>Creatina has been studied for its potential benefits in patients with mitochondrial diseases, including those with leucoencefalopatía<|>5)\n##\n(\"relationship\"<|>ÁCIDO LÁCTICO<|>LEUCOENCEFALOPATÍA<|>Elevated levels of ácido láctico can indicate metabolic issues related to leucoencefalopatía<|>4)\n##\n(\"relationship\"<|>VITAMINA E<|>LEUCOENCEFALOPATÍA<|>Vitamina E has been evaluated for its potential benefits in mitochondrial diseases, which may include leucoencefalopatía<|>3)\n##\n(\"relationship\"<|>DHIROLOPATO<|>LEUCOENCEFALOPATÍA<|>Dihidrolipoato has been studied in the context of mitochondrial diseases, which may include leucoencefalopatía<|>3)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: useas y vómitos tras la\n    comida, episodios de dolor abdominal, diarrea y obstrucción intestinal. Estos síntomas\n    digestivos dan lugar a una importante pérdida de peso y masa muscular (caquexia). La\n    clínica neurológica produce neuropatía periférica en manos y pies, ptosis palpebral, of-\n    talmoplejía por debilidad en la musculatura ocular y sordera. La leucoencefalopatía es\n    un dato característico de la enfermedad. Otras manifestaciones incluyen la cirrosis he-\n    pática con aumento de las transaminasas, esteatosis hepática, anemia, disfunción del\n    sistema nervioso autonómico (hipotensión ortostática), hipertrofia ventricular izquier-\n    da y diverticulosis. El electromiograma y la velocidad de conducción nerviosa muestran\n    un descenso de la velocidad de conducción nerviosa motora y sensorial y cambios\n    miopáticos. Las pruebas de neuroimagen muestran de forma típica alteraciones difusas\n    de la sustancia blanca (leucoencefalopatía).\n\n\n\n             Los hallazgos analíticos característicos del déficit de timidin fosforilasa son ni-\n    veles de timidina y deoxiuridina aumentados en plasma. Puede haber elevación del\n    ácido láctico en el 50% de los pacientes así como de la proteína C reactiva (PCR). El\n    diagnóstico se basa en la medición de la actividad timidina fosforilasa en los leucoci-\n    tos (ausencia de actividad en los individuos sintomáticos y actividad reducida en los\n    individuos heterocigotos asintomáticos) y en el estudio genético.\n\n\n\n             El diagnóstico diferencial debe realizarse con enfermedades que afectan la fos-\n    forilación oxidativa y otras enfermedades mitocondriales, la polineuropatía desmieli-\n    nizante inflamatoria crónica, enfermedades gastrointestinales primarias (dismotilidad\n    gastrointestinal, enfermedad inflamatoria intestinal, enfermedad celíaca, síndrome de\n    colon irritable, trastornos de conducta alimentaria), distrofia muscular congénita por\n    déficit de merosina y las leucodistrofias (enfermedad de Krabbe, adrenoleucodistrofia,\n    enfermedad de Canavan, enfermedad de Alexander, leucoencefalopatía con sustancia\n    blanca evanescente)3 .\n             Actualmente, no se dispone de un tratamiento farmacológico efectivo. Las es-\n    trategias farmacológicas han ido encaminadas al uso de cofactores de la cadena res-\n    piratoria, el tratamiento con antioxidantes, ensayos para la corrección de los déficits\n    bioquímicos secundarios y tratamiento con fármacos para reducir la acumulación de\n    ácido láctico. En muchas ocasiones la evidencia proviene de casos aislados o estudios\n    pequeños. Una revisión sistemática de 2012 identificó 12 ensayos clínicos aleatorizados\n    para evaluar fármacos en las enfermedades mitocondriales sin clara evidencia del uso\n    de ninguna intervención4 . Pese a que no está bien establecida la efectividad, se reco-\n    mienda el tratamiento con coenzima Q 10, creatina y L-carnitina.\n\n\n\n68\n---\n         La coenzima Q 10 ha sido evaluada en enfermedades mitocondriales en un es-\ntudio doble ciego, cruzado. Se observó un aumento estadísticamente significativo en\nla escala global de fuerza muscular y un aumento en los niveles séricos de coenzima Q\n105 . Dado que la coenzima Q 10 es tanto un antioxidante como una parte integral de la\n\ncadena respiratoria mitocondrial, el modesto beneficio en el estudio previo y la falta de\nefectos adversos serios recomiendan el tratamiento en enfermedades mitocondriales,\na dosis de 400 mg/día. Respecto al tratamiento con antioxidantes como idebenona,\nvitamina E, dihidrolipoato no hay datos que evidencien beneficio clínico de su uso.\nEn cuanto a la creatina un estudio cruzado controlado con placebo mostró mejoría en\nalgunas variables con un aumento estadísticamente significativo del 20% en la fuerza\nmedida por dinamómetro. Sin embargo, no hubo mejoría en las actividades de la vida\ndiaria6 . Otro estudio cruzado controlado con placebo que incluye 16 pacientes con en-\nfermedades mitocondriales no encontró ningún beneficio tras 4 semanas de tratamien-\nto con altas dosis de creatina7  . Dada la evidencia de al menos un ensayo controlado\nde un beneficio modesto y seguridad en relación con efectos adversos se recomienda\na dosis de 10 g durante las primeras dos semanas seguidos de 4 g de mantenimien-\nto.\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}